Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02768389 · ClinicalTrials.gov registry record · Early Phase 1
Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma
A Early Phase 1 study, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 18
- Enrollment target
NCT02768389 is a Early Phase 1 study that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 18 participants.
The verdict
NCT02768389, a Early Phase 1 study, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
Patients may participate in this research study if they have glioblastoma. (a brain tumor) that has come back after being treated. Standard treatment for this cancer is a chemotherapy drug called bevacizumab. This research study involves bevacizumab in combination with a special diet called the Modified Atkins Diet (MAD). The purpose of this study is to research if patients can stay on the MAD when it is added to the standard bevacizumab treatment.
Interventions
- DRUG Bevacizumab
- BEHAVIORAL Modified Atkins Diet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2016-09-06 |
| Est. Completion | 2018-11 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02768389
The ClinicalTrials.gov registry entry for NCT02768389 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bevacizumab is the first listed.
NCT02768389 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02768389 about?
NCT02768389 is a clinical study titled "Feasibility Trial of the Modified Atkins Diet and Bevacizumab for Recurrent Glioblastoma". Patients may participate in this research study if they have glioblastoma. (a brain tumor) that has come back after being treated. Standard treatment for this cancer is a chemotherapy drug called bevacizumab. This research study involves bevacizumab in combination with a special diet called the Modi...
What is the current status of trial NCT02768389?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 18 participants. The study started on 2016-09-06. Estimated completion is 2018-11.
What interventions are being tested in trial NCT02768389?
The interventions under investigation include: Bevacizumab (DRUG), Modified Atkins Diet (BEHAVIORAL).
Who is sponsoring clinical trial NCT02768389?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.